Literature DB >> 34100291

An Update on the Routes for the Delivery of Donepezil.

Ze Qiang Zhao1, Bo Zhi Chen1, Xiao Peng Zhang1, Hui Zheng2, Xin Dong Guo1.   

Abstract

Dementia is a significant public health problem in the 21st century. Alzheimer's disease (AD) is an essential factor in dementia. Currently, the drugs used for the treatment of AD are mainly acetylcholine inhibitors (AChEIs). As an AChEI, donepezil (DP) can improve patients' cognitive ability with low side effects and has been accepted by most patients and doctors. For AD patients, the dosage regimen is also crucial due to aging and diseases. Although there are DP oral tablets on the market, there are still many problems to be solved. At present, more and more research is conducted to optimize the route of administration of DP to improve the self-administration of patients. The research fields of DP administration include oral administration, injection administration, intranasal administration, and transdermal administration. This Review is to present the development of different DP administrations and evaluates the advantages and limitations of those works, hoping to optimize the DP dosage regimen for AD patients.

Entities:  

Keywords:  Alzheimer’s disease; donepezil; routes of administration

Mesh:

Substances:

Year:  2021        PMID: 34100291     DOI: 10.1021/acs.molpharmaceut.1c00290

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  1 in total

1.  Intranasal Administration of Nanovectorized Docosahexaenoic Acid (DHA) Improves Cognitive Function in Two Complementary Mouse Models of Alzheimer's Disease.

Authors:  Charleine Zussy; Rijo John; Théo Urgin; Léa Otaegui; Claire Vigor; Niyazi Acar; Geoffrey Canet; Mathieu Vitalis; Françoise Morin; Emmanuel Planel; Camille Oger; Thierry Durand; Shinde L Rajshree; Laurent Givalois; Padma V Devarajan; Catherine Desrumaux
Journal:  Antioxidants (Basel)       Date:  2022-04-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.